3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
2
Pancreatic Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Melanoma
1
Locally Advanced Rectal Adenocarcinoma
1
Locally Advanced Cervical Carcinoma
1
Liver Neoplasms
1
Liver Diseases
1
Head and Neck Neoplasms
1
Gastric Cancer With Liver Metastases
1
Esophageal Neoplasms
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Breast Neoplasms
1
Adenocarcinoma
1
Interventions
pembrolizumab
16
Bevacizumab
12
Carboplatin
10
Nivolumab
8
Pemetrexed
7
Temozolomide
6
Standard of Care
6
Exercise
6
Cetuximab
6
durvalumab
5
atezolizumab
5
Prednisone
5
Cyclophosphamide
5
abemaciclib
4
Paclitaxel
4
Doxorubicin
4
Dexamethasone
4
Cisplatin
4
Blood Specimen Collection
4
temsirolimus
3
enzalutamide
3
dostarlimab
3
daratumumab
3
cabozantinib
3
Rituximab
3
Oxaliplatin
3
Metformin
3
Leucovorin
3
Lenalidomide
3
Ipilimumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Immunotherapy
×
30 days
×
Clear all
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled